
    the trial was prematurely terminated due to a lack of efficacy of the investigational drug.
  
['rheumatoid arthritis']
['anti-tnf-alpha', 'methotrexate', 'placebo', 'ro7123520']

        Inclusion Criteria:

          -  Diagnosis of adult-onset RA as defined by the ACR 2010 criteria, for at least 6 months
             before screening

          -  Moderately to severely active RA as defined by at least 4/28 tender joints and at
             least 4/28 swollen joints, and a DAS28 greater than or equal to (≥) 3.2

          -  For Part 2 only: Active synovitis and/or osteitis as determined by contrast-enhanced
             magnetic resonance imaging

          -  Participants must be taking stable dose of anti-TNF-alpha therapies

          -  Participants on stable oral glucocorticoids within 6 weeks of planned randomization

          -  Participants taking non-steroidal anti-inflammatory drugs (NSAIDs) intermittently (up
             to 2-3 times weekly) for short-term relief of pain and participants on regular NSAID
             use (on stable dose for ≥ 4 weeks)

        Exclusion Criteria:

          -  Parenteral glucocorticoids administration (intramuscular, IV) of ≥50 mg within 6 weeks
             or less than or equal to (≤) 50 milligrams (mg) within 4 weeks prior to planned
             randomization, or scheduled parenteral administrations during the study

          -  Joint(s) injected with intra-articular glucocorticoids or hyaluronic acid within 6
             weeks prior to planned randomization

          -  Active inflammatory diseases of the joints not related to RA

          -  Systemic autoimmune disease other than RA

          -  Juvenile idiopathic arthritis or juvenile RA and/or RA developed before the age of 16

          -  Active fibromyalgia that makes appropriate assessment of RA disease activity
             challenging in the opinion of the Investigator

          -  RA participants functional status class IV according to the ACR 1991 criteria

          -  Participants with severe chronic or recurrent viral, bacterial, parasitic, or fungal
             infections

          -  History of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human
             immunodeficiency virus (HIV) infection

          -  Any identified confirmed congenital or acquired immunodeficiency

          -  Abnormal laboratory values and liver function test

          -  Myocardial infarction within less than 6 months prior to participation in the study

          -  Severe central or peripheral nervous system diseases
      